Clinical Trials Directory

Trials / Completed

CompletedNCT00210821

Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches

A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
347 (actual)
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the effectiveness and safety of two treatment regimens in preventing migraines. The antidepressant amitriptyline has been used successfully to prevent migraine headaches.

Detailed description

People who suffer from migraines have many prescription medications to choose from, both to treat the migraine and to prevent it from starting. However, many patients have not had success in finding the drug that helps them best. Amitriptyline, an antidepressant, has been used successfully for many years to prevent migraine headaches. This study will compare the effectiveness of amitriptyline with the effectiveness of topiramate, an anti-seizure drug, in preventing migraines. The safety of both drugs will also be assessed. The objective of the study is to demonstrate that topiramate will be at least as effective as amitriptyline in preventing migraines. During the first 4 weeks of the study, topiramate or amitriptyline will be increased by 25 mg per week up to a total dose of 100 mg per day or up to the maximum tolerated dose, whichever is less. Treatment will continue at 100 mg per day for 22 weeks.

Conditions

Interventions

TypeNameDescription
DRUGtopiramate

Timeline

Start date
2004-02-01
Completion
2005-11-01
First posted
2005-09-21
Last updated
2011-06-10

Source: ClinicalTrials.gov record NCT00210821. Inclusion in this directory is not an endorsement.